Trial approved for Alzheimer’s treatment

Israel’s SciSparc to commence a Phase 2a clinical trial of its SCI-110 (formerly THX-110) treatment for patients with Alzheimer’s disease (AD) and agitation. The study will be conducted at the Israeli Medical Center for Alzheimer’s.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *